Partners: ANR, ISCIII, Ministero della Salute, DLR
The potential of personalised medicine (PM) is to improve prevention, diagnosis and treatment of diseases by taking into account individuals' genotypes and phenotypes as well as other biomedical, life style and environmental data. However, with some exceptions in cancer and rare diseases, PM has not yet arrived in clinical practice due to fragmentation, undefined legal and regulatory frameworks and its unclear economic value. To overcome these hurdles, ICPerMed was founded to initiate and support communication and exchange on PM research, funding and implementation. ICPerMed provides a platform to identify the requirements for a suitable framework in terms of infrastructures, resources and regulatory procedures to foster the development and implementation of PM. The ICPerMed Secretariat will continue to substantially contribute to the success of ICPerMed by efficiently coordinating all consortium activities. This includes supporting the ICPerMed governance and working groups as well as organising ICPerMed internal meetings and thematic events. A further important task of the ICPerMed Secretariat will be the implementation of an effective dissemination plan and the assistance in the development of a sustainability strategy. By monitoring ongoing research funding activities and collecting “Best Practice Examples”, the secretariat will provide the basis for evidence informed allocation of research funding and regulatory framework and standard development. The ICPerMed Secretariat will guide the dialogue with relevant stakeholders and initiatives. It will support training measures in PM in order to facilitate implementation of PM into practice. The organisational and logistical support of a secretariat will maximise the unique and long-term impact of ICPerMed by strengthening Europe's leading role in the successful implementation of PM in the global context.
Partners: IARC, ISCIII, DHM, Maria Sklodowska-Curie National Research Institute of Oncology
The WHO Classification of Tumours (WCT) underpins cancer diagnosis, and hence treatment and care of cancer patients, as well as research into cancer epidemiology, prevention, diagnosis, and treatment. However, decisions for such a global reference tool are not always informed by the best available evidence, and risks of incorporating misinformation into the clinical decisions pathway exist. We aim to develop a tool that maps existing evidence, showing gaps, identifying pockets of low-level evidence, and synthesis of reliable evidence. The tool will map the evidence base of the WCT in order to facilitate evidence-based decision-making in pathology, and promote the application of higher research standards in the field. We will adapt the recently developed Evidence Gap Map (EGM) methodology, first time ever to be used in biomedicine. The resulting EGMs will increase the discoverability and use of studies by the WCT decision-makers, research commissioners, researchers and others. Our WCT-EVI-MAP project is organized in three subsequent phases, where we will apply a stepwise approach to: first, develop a framework and define evidence levels based on expert consensus; second, elaborate a series of Megamaps in iterative cycles describing evidence of all tumour types; third, perform a descriptive analysis of the use of evidence in a continuous updated exercise. To overcome identified challenges, several strategies are proposed, such as using recent advances in technologies, following a strict multidisciplinary approach and integrating this project into the WCT strategic planning for the 6th edition. We believe that the WCT EVI-MAP will represent a ground-breaking advance for the WCT and research in the field, and will accelerate progress in cancer diagnosis and management. Integration of evidence-based medicine methods has been shown to have a positive impact in other specialized medical fields and our project represents a first step towards an evidence-based pathology.